• Cardiff Oncology launched a registered direct offering with warrants covering 9,303,136 common shares.
• Warrants priced alongside shares at USD 1.05, with officer and director participation at USD 1.44.
• Warrants carry a USD 1.31 exercise price, become exercisable after six months and authorized-share approval, expire 5.5 years later.
• Gross proceeds expected at about USD 10 million; closing targeted for July 16, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150800PRIMZONEFULLFEED9762518) on July 15, 2026, and is solely responsible for the information contained therein.